Replies to post #202 on Fate Therapeutics Inc (FATE)

[NY1972]

Our finding that glioblastoma cells leveraged cellular constituents in their microenvironment to protect themselves from the deleterious effects of cancer therapeutics is reminiscent of
findings reported in breast and ovarian cancer, where the percentage of stromal cells in the clinical specimen prognosticated survival after systemic therapy

https://www.pnas.org/doi/pdf/10.1073/pnas.2009290118

[NY1972]

Looks like changing M2 to M1 with a high dose small molecule + anti-PD1 will be enough. Unleashing trojan horses inside the fortress is the best strategy.